Abstract
Osteoporosis - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report,
“Osteoporosis - Pipeline Assessment and Market Forecasts to 2017”.
The report is an essential source of information and analysis on the global
Osteoporosis therapeutics market. The report identifies the key trends shaping
and driving the global Osteoporosis therapeutics market. The report also
provides insights into the competitive landscape and the emerging players
expected to significantly alter the positions of the existing market leaders.
Most importantly, the report provides valuable insights into the pipeline
products within the global Osteoporosis sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by
GlobalData’s team of industry experts.
The global osteoporosis therapeutics market was valued at $9.6 billion in
2009. It is expected to grow to $18.2 billion by 2017 at a Compound Annual
Growth Rate (CAGR) of 8.2%. This significant growth is primarily attributed to
the strong current treatment options as well as strong pipeline candidates. An
increase in the prevalence of osteoporosis among the female population is the
principal driver of the osteoporosis market and will continue to be in the
future. The significant reason for the increase in prevalence is due to the
decline in the use of Hormone Replacement Therapy (HRT) in healthy
postmenopausal women. HRT has been used to help prevent the bone loss that
leads to osteoporosis. However, recent negative study results, showing an
increased risk of heart attacks, stroke, breast cancer and blood clots, have
led to a decline in HRT usage. Therefore, a decline in the use of HRT and an
increase in the diseased population will combine to contribute to the
increased burden of osteoporosis.
Scope
The scope of the report includes:
- Annualized global Osteoporosis
therapeutics market revenue data from 2001 to 2009, forecast for eight years
to 2017.
- Geographies covered in this report include the United States
(US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
-
Pipeline analysis data provides a split across the different phases,
mechanisms of action being developed and emerging trends. The molecules under
development for osteoporosis can be categorized as calcium modulators, CTSK
inhibitors, bone-tissue resorption inhibitors and SERMs.
- Analysis of the
current and future market competition in the global osteoporosis therapeutics
market. The key future market players covered are Amgen, Ligand
Pharmaceuticals Incorporated, Osteologix, Novartis AG, GlaxoSmithKline Inc,
- Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide a qualitative
analysis of its implications.
- Key topics covered include a strategic
competitor assessment, a market characterization, the unmet needs and the
implications for the osteoporosis market.
Reasons to buy
The report will enhance your decision making capability. It will allow you
to:
- Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies and by identifying the
companies with the most robust pipelines.
- Develop business strategies by
understanding the trends shaping and driving the global Osteoporosis
therapeutics market.
- Drive revenues by understanding the key trends,
innovative products and technologies, market segments and companies likely to
affect the global Osteoporosis therapeutics market in the future.
-
Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analyzing the performance of various competitors.
- Identify the emerging players with potentially strong product
portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the
market categories and segments that present the best opportunities for
consolidation, investments and strategic partnerships.
- What’s the
next big thing in the global Osteoporosis therapeutics market landscape?
Identify, understand and capitalize.
Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2
Osteoporosis Therapeutics Market: Introduction 6
2.1 GlobalData Pipeline
Report Guidance 6
3 Osteoporosis Therapeutics Market: Market
Characterization 7
3.1 Osteoporosis Therapeutics Market Size 7
3.2
Osteoporosis Therapeutics Market Forecast and CAGR 8
3.3 Drivers and
Barriers for the Osteoporosis Therapeutics Market 9
3.3.1 Drivers for the
Osteoporosis Therapeutics Market 9
3.3.2 Barriers for the Osteoporosis
Therapeutics Market 10
3.4 Opportunity and Unmet Need 11
3.5 Key
Takeaway 12
4 Osteoporosis Therapeutics Market: Competitive Assessment
13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3
Product Profile for the Major Marketed Products in the Osteoporosis
Therapeutics Market 14
4.3.1 Fosamax (alendronate sodium) 14
4.3.2
Actonel (risedronate sodium) 15
4.3.3 Evista (raloxifene hydrochloride)
18
4.3.4 Boniva (ibandronate sodium) 20
4.3.5 Forteo 21
4.3.6
Reclast (zoledronic acid) 22
4.3.7 EVISTA (Raloxifene) 23
4.4 Key
Takeaway 24
5 Osteoporosis Therapeutics Market: Pipeline Assessment 25
5.1 Overview 25
5.2 Strategic Pipeline Assessment 25
5.2.1 Technology
Trends Analytic Framework 25
5.3 Osteoporosis Therapeutics -
Promising Drugs under Clinical Development 26
5.4 Molecule Profiles for
Promising Drugs under Clinical Development 27
5.4.1 Prolia (denosumab)
27
5.4.2 MK-0822 (odanacatib) 27
5.4.3 Viviant (bazedoxifene) 28
5.4.4 PREOS (parathyroid hormone 1-84 injection) 29
5.5 Osteoporosis
Therapeutics Market - Clinical Pipeline by Mechanism of Action 30
5.6 Osteoporosis Therapeutics Pipeline - Pipeline by Clinical Phase of
Development 31
5.6.1 Osteoporosis Therapeutics - Phase III Clinical
Pipeline 32
5.6.2 Osteoporosis Therapeutics - Phase II Clinical
Pipeline 33
5.6.3 Osteoporosis Therapeutics - Phase I Clinical
Pipeline 34
5.6.4 Osteoporosis Therapeutics - Preclinical Pipeline
34
5.7 Key Takeaway 34
6 Osteoporosis Therapeutics Market:
Implications for Future Market Competition 35
7 Osteoporosis Therapeutics
Market: Future Players in the Osteoporosis Therapeutics Market 36
7.1
Introduction 36
7.2 Amgen 36
7.2.1 Overview 36
7.2.2 Osteoporosis
Portfolio 37
7.3 Merck 37
7.3.1 Overview 37
7.3.2 Osteoporosis
Portfolio 37
7.4 Pfizer 37
7.4.1 Overview 37
7.4.2 Osteoporosis
Portfolio 38
7.5 NPS Pharmaceuticals, Inc. 38
7.5.1 Overview 38
7.5.2 Business Description 38
7.6 Chugai Pharmaceutical Co., Ltd. 39
7.6.1 Company Overview 39
7.6.2 Business Description 39
7.7 Zelos
Therapeutics, Inc. 40
7.7.1 Company Overview 40
7.8 Novartis AG 41
7.8.1 Company Overview 41
7.8.2 Business Description 41
7.9
GlaxoSmithKline plc 42
7.9.1 Company Overview 42
7.9.2 Business
Description 42
8 Osteoporosis Therapeutics Market: Appendix 44
8.1
Definitions 44
8.2 Scope of Pipeline Research 45
8.3 Research
Methodology 45
8.3.1 Coverage 45
8.3.2 Secondary Research 45
8.3.3
Forecasting 46
8.3.4 Primary Research 48
8.3.5 Expert Panel Validation
49
8.4 Contact Us 49
8.5 Disclaimer 49
8.6 Sources 50
1.1
List of Tables
Table 1: Osteoporosis Therapeutics Market, Global, Revenue
($bn), 2001-2009 7
Table 2: Osteoporosis Therapeutics Market,
Global, Market Forecasts ($bn), 2009-2017 8
Table 3: Drugs Approved
by the FDA to Prevent and/or Treat Osteoporosis, 2010 13
Table 4: Effect
of Actonel 5mg on the Risk of Vertebral Fractures, 2010 17
Table 5: Mean
Percentage Increases in BMD from Baseline in Patients Taking Actonel 5mg, 2010
17
Table 6: Effect of Evista on Risk of Vertebral Fractures, 2010 19
Table 7: Evista, (60mg Once Daily) Related Increases in BMD for the
Osteoporosis Treatment vs. Placebo 19
Table 8: Effect of Forteo on
Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis, 2010
22
Table 9: Mean Percentage Change in BMD in Postmenopausal Women with
Osteoporosis, 2010 22
Table 10: Major Marketed Products in the
Osteoporosis Therapeutics Market, 2010 24
Table 11: Osteoporosis
Therapeutics - Most Promising Drugs Under Clinical Development, 2010
26
Table 12: Osteoporosis Therapeutics - Approved and NDA filed
Clinical Pipeline, 2010 31
Table 13: Osteoporosis Therapeutics -
Phase III Clinical Pipeline, 2010 32
Table 14: Osteoporosis Therapeutics
- Phase II Clinical Pipeline, 2010 33
Table 15: Osteoporosis
Therapeutics - Phase I Clinical Pipeline, 2010 34
Table 16:
Osteoporosis Therapeutics - Preclinical and Discovery Pipeline, 2010
34
Table 17: Amgen - Osteoporosis Pipeline Products, 2010 37
Table 18: Merck - Osteoporosis Pipeline Products, 2010 37
Table 19:
Pfizer - Osteoporosis Pipeline Products, 2010 38
1.2 List of
Figures
Figure 1: Osteoporosis Therapeutics Market, Global, Revenues
($bn), 2001-2009 7
Figure 2: Osteoporosis Therapeutics Market,
Global, Market Forecasts ($bn), 2009-2017 8
Figure 3: Opportunity
and Unmet Need in the Osteoporosis Therapeutics Market, 2010 11
Figure 4:
Strategic Competitor Assessment of the Major Marketed Products for
Osteoporosis, 2010 14
Figure 5: Technology Trends Analytic Framework of
the Osteoporosis Therapeutics Pipeline, 2010(Preclinical and Discovery)
25
Figure 6: Technology Trends Analytic Framework of the Osteoporosis
Therapeutics Pipeline, 2010 26
Figure 7: Osteoporosis Therapeutics
Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010 30
Figure 8: Osteoporosis Therapeutics Pipeline by Phase of Clinical Development,
2010 31
Figure 9: Implications for Future Market Competition in the
Osteoporosis Therapeutics Market, 2010 35
Figure 10: Osteoporosis -
Clinical Pipeline by Company, 2010 36
Figure 11: GlobalData Market
Forecasting Model, 2010 48
